PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP

GlyphAgo shows 6.8-fold higher bioavailability and sharply reduced PK variability in Phase 1.

What the company is saying

PureTech Health plc (LSE:PRTC) and its Founded Entity, Seaport Therapeutics (NASDAQ:SPTX), are highlighting the first scientific presentation of detailed Phase 1 pharmacokinetic data for GlyphAgo (SPT-320) at the ECNP Congress in Munich, Germany. The announcement emphasizes a 6.8-fold increase in agomelatine bioavailability and a 10-fold reduction in pharmacokinetic variability versus unmodified agomelatine, with specific geometric CV% ranges disclosed for both AUC₀-₂₄ and Cmax. The company frames GlyphAgo as a differentiated oral prodrug designed to bypass first-pass liver metabolism, aiming to reduce liver enzyme risks and monitoring needs that have limited agomelatine's clinical use. Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics, is the named presenter, lending technical credibility. The tone is confident and data-driven, but also forward-looking, with claims about potential clinical advantages and future leadership in the GAD treatment space. The company discloses that a Phase 2a trial is underway with topline results expected in early 2028, and a Phase 2/3 trial is planned for the first half of 2027.

What the data suggests

The Phase 1 trial involved 174 healthy volunteers and demonstrated a statistically significant 6.8-fold increase in agomelatine bioavailability for GlyphAgo compared to the unmodified drug. Pharmacokinetic variability (geometric CV%) for GlyphAgo in the single ascending dose portion ranged from 12.9% to 26.6% for AUC₀-₂₄ and 17.1% to 50.5% for Cmax, compared to 200% and 217% for unmodified agomelatine. In the crossover portion, GlyphAgo's variability ranged from 22.6% to 29.7% for AUC₀-₂₄ and 26.5% to 44.0% for Cmax, while unmodified agomelatine ranged from 234.6% to 350.1% and 303.7% to 500.9%, respectively. The data also show no food effect, no accumulation over seven days, and no impact from estrogen-containing oral contraceptives, supporting the claim that GlyphAgo bypasses hepatic metabolism. The evidence is robust for improved PK properties, but no efficacy or safety outcomes are disclosed beyond these pharmacokinetic endpoints. The company has initiated a Phase 2a trial and plans a Phase 2/3 trial, but topline efficacy and safety data will not be available until at least early 2028.

Analysis

The announcement presents robust Phase 1 pharmacokinetic data for GlyphAgo, with detailed numerical evidence supporting improved bioavailability and reduced variability versus unmodified agomelatine. These realised results are clearly disclosed and credible. However, the tone is notably optimistic about future clinical and commercial potential, with multiple forward-looking statements regarding upcoming Phase 2a and Phase 2/3 trials, topline results not expected until 2028, and aspirations for GlyphAgo to become a leading treatment. The release also flags the need for substantial additional funding, but provides no financial or profitability metrics, and the timeline for any commercial or earnings impact is long-term. The gap between the strong Phase 1 data and the ambitious future claims, combined with the capital intensity and long execution distance, results in moderate narrative inflation.

Risk flags

• ●Clinical development risk is high, as the current evidence is limited to pharmacokinetic improvements without efficacy or safety data in patients with generalized anxiety disorder. Success in Phase 1 does not guarantee positive outcomes in later-stage trials.
• ●Execution risk is significant due to the long timelines: topline Phase 2a results are not expected until early 2028, and the Phase 2/3 trial will not start until the first half of 2027. Delays or negative results in these trials could materially impact the program.
• ●Financial risk is present, as the company explicitly states a need for substantial additional funding to complete development and commercialize any product, with no current disclosure of secured capital or partnership agreements.
• ●Regulatory risk remains, since GlyphAgo's clinical claims are not yet supported by efficacy or safety data in the target patient population, and approval in new markets will depend on future trial outcomes.

Bottom line

This announcement demonstrates that GlyphAgo delivers a 6.8-fold increase in agomelatine bioavailability and sharply reduced pharmacokinetic variability compared to the unmodified drug, based on data from 174 healthy volunteers. The technical data are credible and detailed, but the story remains early-stage, as no efficacy or safety results in patients with generalized anxiety disorder have been disclosed. The next major catalyst—Phase 2a topline data—is not expected until early 2028, and a pivotal Phase 2/3 trial will only begin in the first half of 2027. The company faces substantial clinical, execution, and funding risks before any commercial value can be realized. Investors should focus on the long timeline to potential value and the need for additional capital, with the most important takeaway being that while the PK data are strong, clinical efficacy and safety remain unproven and are several years from resolution.

Announcement summary

(LSE:PRTC) (NASDAQ:SPTX) PureTech Health plc announced that its Founded Entity, Seaport Therapeutics, presented additional pharmacokinetic data from the Phase 1 clinical trial of GlyphAgo™ (SPT-320 or Glyph Agomelatine) at the 39th European College of Neuropsychopharmacology (ECNP) Congress, held October 10-13, 2026, in Munich, Germany. This marks the first scientific presentation of detailed data from the GlyphAgo Phase 1 program, providing comprehensive pharmacokinetic analyses that reinforce previously reported topline results and highlight GlyphAgo's differentiated profile. GlyphAgo is a novel, "Glyphed" oral prodrug of agomelatine designed to enhance lymphatic absorption and bypass first-pass liver metabolism. In the Phase 1 program, GlyphAgo demonstrated a statistically significant 6.8-fold increase in bioavailability of agomelatine compared to unmodified agomelatine and showed significantly lower (10-fold) pharmacokinetic (PK) variability. The completed multi-part Phase 1 proof-of-concept trial evaluated safety, tolerability, and pharmacokinetics in 174 healthy volunteers. The single- and multiple-ascending dose portions of the trial demonstrated dose-dependent increases in agomelatine exposure, no food effect, and no accumulation of exposure over seven days of dosing. In the single ascending dose (SAD) portion, PK variability (geometric CV%) for GlyphAgo ranged from 12.9% to 26.6% for AUC₀-₂₄ and from 17.1% to 50.5% for Cmax, compared with 200% and 217%, respectively, for unmodified agomelatine. In the crossover portion, PK variability for GlyphAgo ranged from 22.6% to 29.7% for AUC₀-₂₄ and from 26.5% to 44.0% for Cmax, compared with 234.6% to 350.1% and 303.7% to 500.9%, respectively, for unmodified agomelatine. The data also showed no effect of estrogen-containing oral contraceptives on agomelatine exposure following GlyphAgo dosing. Seaport has initiated a Phase 2a clinical trial evaluating GlyphAgo in adults with generalized anxiety disorder (GAD) and sleep disturbance, with topline results expected in early 2028. The company also plans to initiate a Phase 2/3 clinical trial evaluating the efficacy and safety of GlyphAgo in patients with GAD in the first half of 2027. Daniel Bonner, Ph.D., Co-Founder and Senior Vice President, Platform, at Seaport Therapeutics, presented the poster (PS02-2029) at the ECNP Congress on October 11, 2026. GlyphAgo is approved for the treatment of GAD in Australia and Major Depressive Disorder in Australia and the European Union. Seaport Therapeutics is a clinical-stage therapeutics company focused on developing new medicines for depression, anxiety, and other neuropsychiatric disorders using its proprietary Glyph™ platform.

Disagree with this article?